Aprea Therapeutics AB, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, today presented clinical data...

Important clinical study results from one of Eli Lilly and Company's (NYSE: LLY) ongoing immuno-oncology collaborations with Merck (known as MSD outside the U.S. and Canada) were announced today...

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced safety and preliminary efficacy data from a phase 1 study of DS-8201a, a novel investigational HER2-targeting antibody...

SYSTRAN, a global leader in language translation technology, will demo two new integrations for SYSTRAN's offering of Relativity at Relativity Fest 2016 this Sunday in Chicago. SYSTRAN is...

Results from the pivotal Phase III MONALEESA-2 study show LEE011 (ribociclib) plus letrozole significantly extended progression-free survival (PFS) compared to a standard of care, letrozole, as a...